1Hammond ME, Hayes DF, Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[ J ]. J Clin Oncol, 2010,28(16) :2784-2795.
2McGuire W, Carbone PP, Sears ME, et al. Estrogen receptors in human breast cancer [ J ]//McGuire WL, Carbone PP, Vollmer EP. Estrogen receptors in human breast cancer. New York: Raven Press, 1975 : 1-7.
3Cowen PN, Teasdale J, Jackson P, et al. Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay[ J]. Histopathology, 1990,17 (4) :319-325.
4Badve SS, Baehner FL, Gray RP, et al. Estrogen and progesterone receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory[ J]. J Clin Oncol, 2008,26(15) :2473-2481.
5Osborne CK, Yochmowitz MG, Knight WA 3rd, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer[J]. Cancer,1980,46(12) :2884-2888.
6Knight WA 3rd, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer [ J ]. Clin Endocrinol Metab,1980 ,9 (2) :361-368.
7Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistoehemistry is superior to the ligand-bindingassay for predicting response to adjuvant endocrine therapy in breast cancer[ J ]. J Clin 0nco1,1999,17 (5) : 1474-1481.
8Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study [ J ]. Mod Patho1,2004,17 (5) : 1545-1554.
9Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[ J]. Clin Cancer Res, 2006,12( 15 ) : 4614-4618.
10Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer [ J ]. Breast Cancer,2006,13 ( 1 ) :74-83.
10Kiyose S, Igarashi H, Nagura K, et al. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immuno- histoehemistry (IHC) and fluorescence in situ hybridization (FISI-I)[J]. Pathol Int,2012,62(11) :728-734.
